The dog days of summer are heating up on Wall Street with a fresh batch of stocks garnering rapturous buy ratings and lofty price targets from top analysts. For investors seeking the cream of the market's crop, this elite group of 8 picks checks all the boxes.
Let's dive into the pinpoint analysis backing why these tickers have the Street's brightest minds shouting from the rooftops:
Waystar Holding (WAY) - The $24 price target from Barclays' Stephanie Davis spotlights over 20% upside for this healthcare payments software play. Leveraging AI and robotic process automation, WAY boasts an annualized revenue run rate over $1 billion as it transforms how providers get paid. The numbers speak for themselves.
Constellation Brands (STZ) - High-end beer, wine and spirits perfection earns STZ unequivocal support from TD Cowen's Robert Moskow. His $300 target reflects confidence in brand power gems like Corona, Modelo and Kim Crawford amidst enduring pricing strength. Every sip is pure profit.
Stunning Admission from a Wall Street Millionaire
He predicted the rise of the Internet… the financial crisis of 2008… and many of the most famous stocks of the last 25 years – including Amazon, Apple, and Netflix, before they were household names.(So many of his predictions came true, CNBC nicknamed him "The Prophet.").
Now, this Wall Street millionaire is telling folks, "Here's exactly where I'd be putting my money in 2024."
AstraZeneca (AZNCF) - The biotech titan's cutting-edge pipeline spanning cardiovascular, oncology and respiratory drugs sparked Barclays' Emily Field to pound the table. Her £155 ($171) target showcases massive growth potential as new meds fuel future cash flows.
GitLab (GTLB) - Bank of America's Koji Ikeda has GTLB among his top software picks, slapping an $80 price objective on the leading DevOps platform pioneer. As enterprises evolve digital workflows, GTLB's elite solutions position it to capitalize on this multi-billion dollar market.
Eli Lilly (LLY) - Morgan Stanley's Terence Flynn is betting big on blockbuster diabetes, obesity and Alzheimer's treatments driving LLY to $1,023 per share within a year. The Street's highest LLY price target reflects soaring conviction in its innovative drug pipeline.
AT&T (T) - Don't overlook the mobile telecom behemoth adding media tentacles like HBO as Barclays' Kannan Venkateshwar reaffirms his bullish $20 target. With a juicy 6% dividend yield blending growth and income, investors have every reason to keep "T" dialed in.
First Solar (FSLR) - Robert W. Baird's Ben Kallo sees nothing but clear skies for this $307-bound solar panel titan. FSLR's high efficiency thin-film modules are capturing serious wallet share as clean energy demand explodes worldwide.
Crinetics Pharma (CRNX) - Yasmeen Rahimi at Piper Sandler is betting up to $97 per share on CRNX's pipeline of rare endocrine treatments disrupting large markets. Fresh catalysts ahead for this under-the-radar biotech with blockbuster aspirations.
From cash-gushing blue-chip titans like Constellation and AT&T to disruptive upstarts attacking massive healthcare and energy markets, this portfolio of 8 sizzlers is built to thrive as summer gives way to autumn's harvest season.
The common thread? Elite Street cred courtesy of prize analysts making the financial world's smartest investors take notice. When cut-through billionaires and fund managers get laser-focused on specific opportunities, it pays to join them for the ride.
These Wall Street darling stocks are heating up for good reason. Get them on your watchlist now before their runaway rallies leave profit-takers behind in the rearview mirror.
